Maze Therapeutics, Inc.

Overview

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. The company's lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1 (APOL1), currently in phase II clinical trials for APOL1-mediated kidney disease, and MZE782, an oral small molecule inhibitor in phase II-ready clinical trials for phenylketonuria and chronic kidney disease. Additionally, Maze Therapeutics is developing MZE001, an investigational oral small molecule inhibitor targeting muscle-specific glycogen synthase for the treatment of Pompe disease. The company has established partnerships with organizations such as Trace Neuroscience, Inc., Shionogi & Co., Ltd., and Neurocrine Biosciences, Inc. to advance its research and development efforts. Maze Therapeutics was formerly known as Modulus Therapeutics, Inc. and changed its name in September 2018. The company was incorporated in 2017 and is headquartered in South San Francisco, California. As of June 11, 2026, Maze Therapeutics is publicly traded on the NASDAQ under the ticker symbol MAZE, with a market capitalization of approximately $1.31 billion. The company's stock price is $24.38, reflecting a 3.04% increase from the previous close. The latest trade occurred at 3:03 PM UTC on June 11, 2026. The stock has a price-to-earnings ratio of -10.37 and an earnings per share of -$2.35. The company's financial performance and stock information are subject to market fluctuations and should be reviewed in the context of the broader biotechnology sector. Investors are encouraged to conduct thorough due diligence and consult financial advisors before making investment decisions. Maze Therapeutics continues to focus on advancing its pipeline of precision medicines, aiming to address unmet medical needs in the fields of kidney and metabolic diseases. The company's commitment to innovation and strategic partnerships positions it as a key player in the biopharmaceutical industry, with ongoing efforts to bring transformative therapies to patients in need. Maze Therapeutics remains dedicated to its mission of improving patient outcomes through the development of targeted, effective treatments, leveraging its expertise in precision medicine and its collaborative approach to research and development. The company's ongoing clinical trials and research initiatives reflect its dedication to scientific excellence and patient-centric solutions, contributing to the advancement of healthcare and the potential for significant impact in the treatment of complex diseases.